Dr. Simon Read Joins Dianthus Therapeutics Board
Dr. Simon Read has been appointed to the Board of Directors of Dianthus Therapeutics, Inc. This decision comes as the company continues to pave the way in developing antibody complement therapeutics aimed at treating severe autoimmune diseases.
Expertise in Biopharmaceuticals
With over 30 years in the biopharmaceutical industry, Dr. Read brings a wealth of knowledge and leadership experience. He is known for his success as the CEO and Founder of Mariana Oncology and served as the Chief Scientific Officer at Ra Pharma. His leadership has driven significant advancements and innovations in drug development.
Transition on the Board
Alongside Dr. Read's exciting appointment, Lonnie Moulder will be stepping away from his role on the Board of Directors. Alison Lawton, Chair of Dianthus, expressed her gratitude for Moulder's contributions, citing his vital support during the company's rapid growth from a private to a publicly traded entity.
Recognizing Contributions and Looking Ahead
Lonnie Moulder highlighted the impressive progress Dianthus has made, particularly in advancing its complement inhibitors since initial investments started in 2019. His optimism for Dianthus' future underscores a strong foundation that supports ongoing clinical trials.
Dr. Read's Background
Before joining Dianthus, Dr. Read's career featured significant roles at GlaxoSmithKline, AstraZeneca, and Roche/Genentech. He was instrumental in the clinical development of prominent immunology drugs, which contributes to his expertise today.
Commitment to Innovation
In his new position, Dr. Read expressed enthusiasm about collaborating with the Dianthus team, especially concerning the forthcoming Phase 2 MaGic trial results expected soon. He believes DNTH103 holds the potential to become a groundbreaking therapy for patients with severe neuromuscular disorders.
About Dianthus Therapeutics
Dianthus Therapeutics stands at the forefront of biopharmaceutical innovation, focusing on the design and delivery of cutting-edge monoclonal antibodies. The company operates from its bases in New York City and Waltham, aiming to create transformative therapies for patients battling severe autoimmune and inflammatory diseases.
Company Vision and Future Goals
With a dedicated team of industry veterans, Dianthus continues to make strides in research and development, bolstered by a commitment to creating therapies that significantly improve patient outcomes.
Contact Information
For further inquiries, please reach out to:
Jennifer Davis Ruff
Dianthus Therapeutics
jdavisruff@dianthustx.com
Frequently Asked Questions
Who is Dr. Simon Read?
Dr. Simon Read is a biopharmaceutical expert with over 30 years of experience and has been appointed to Dianthus Therapeutics' Board of Directors.
What role did Lonnie Moulder play at Dianthus?
Lonnie Moulder served on the Board of Directors and played a crucial role in guiding Dianthus' growth from a private entity to a public company.
What is DNTH103?
DNTH103 is a potential therapeutic designed by Dianthus Therapeutics aimed at treating severe neuromuscular conditions, currently in Phase 2 trials.
What is the focus of Dianthus Therapeutics?
Dianthus focuses on developing advanced antibody therapies to address severe autoimmune and inflammatory diseases.
How can I learn more about Dianthus Therapeutics?
You can visit their official website at www.dianthustx.com.